Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
S Petersohn, X Pouwels, B Ramaekers… - European journal of …, 2020 - academic.oup.com
Background Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
S Petersohn, X Pouwels… - European Journal …, 2020 - cris.maastrichtuniversity.nl
Background Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
S Petersohn, X Pouwels, B Ramaekers… - European Journal …, 2020 - journals.sagepub.com
Background Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
[HTML][HTML] Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
S Petersohn, X Pouwels, B Ramaekers… - European Journal of …, 2020 - ncbi.nlm.nih.gov
Background Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study.
S Petersohn, X Pouwels, B Ramaekers… - European Journal …, 2020 - search.ebscohost.com
Background: Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg
aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for …
aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for …
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
S Petersohn, X Pouwels… - European journal …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study.
S Petersohn, X Pouwels, B Ramaekers… - European Journal of …, 2020 - europepmc.org
Background Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
[PDF][PDF] Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
S Petersohn, X Pouwels, B Ramaekers… - Cardiology, 2020 - ris.utwente.nl
Background: Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100mg aspirin
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the …
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
S Petersohn, X Pouwels, B Ramaekers… - European journal of …, 2020 - research.utwente.nl
Background: Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg
aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for …
aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for …